Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis

Vlad Ratziu, Marwan Ghabril, Manuel Romero-Gomez, Gianluca Svegliati-Baroni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The prevalence of nonalcoholic liver disease (NAFLD) is increasing worldwide in conjunction with the epidemic increase in obesity and metabolic risk factors. Consequently, NAFLD has become a leading indication for liver transplantation. Although genetic factors play an important role in the pathogenesis of NAFLD, detrimental lifestyle trends favoring a calorically unrestricted diet rich in carbohydrates and unsaturated fat, prolonged sedentary periods or limited physical activity have major metabolic implications. In aggregate these physiological dysregulations constitute the main risk factors for the metabolic syndrome and NAFLD. The cornerstone of the treatment of NAFLD, is lifestyle changes, including modifications to diet and physical activity, to reduce body weight and liver fat, however adherence is notoriously poor and the epidemic of NAFLD continues to grow unimpeded. In the face of this unmet clinical need, the pharmacologic therapy of NAFLD has been expanding as the varied mechanistic pathways of NAFLD are elucidated. Beyond these approaches to treating NAFLD, the prevention of other liver diseases is additionally important. Chief among these is alcoholic liver disease, and heavy use is detrimental irrespective of underlying NAFLD. However, the impact of mild to moderate alcohol use in patients with mild or nonadvanced forms NAFLD is undefined. This article summarizes the results of the International Liver Transplantation Society consensus meeting on NAFLD in liver transplantation. It describes the available evidence and provides consensus guidance on the lifestyle and pharmacologic therapies of NAFLD, and the consensus position on alcohol use in patients with NAFLD.

Original languageEnglish (US)
Pages (from-to)28-38
Number of pages11
JournalTransplantation
Volume103
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Therapeutics
Life Style
Consensus
Non-alcoholic Fatty Liver Disease
Liver Transplantation
Liver Diseases
Unsaturated Fats
Alcohols
Exercise
Diet Therapy
Alcoholic Liver Diseases
Obesity
Fats
Body Weight
Carbohydrates
Diet
Liver

ASJC Scopus subject areas

  • Transplantation

Cite this

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. / Ratziu, Vlad; Ghabril, Marwan; Romero-Gomez, Manuel; Svegliati-Baroni, Gianluca.

In: Transplantation, Vol. 103, No. 1, 01.01.2019, p. 28-38.

Research output: Contribution to journalArticle

Ratziu, Vlad ; Ghabril, Marwan ; Romero-Gomez, Manuel ; Svegliati-Baroni, Gianluca. / Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. In: Transplantation. 2019 ; Vol. 103, No. 1. pp. 28-38.
@article{f3bff6f0398d49e690de3e052abf117d,
title = "Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis",
abstract = "The prevalence of nonalcoholic liver disease (NAFLD) is increasing worldwide in conjunction with the epidemic increase in obesity and metabolic risk factors. Consequently, NAFLD has become a leading indication for liver transplantation. Although genetic factors play an important role in the pathogenesis of NAFLD, detrimental lifestyle trends favoring a calorically unrestricted diet rich in carbohydrates and unsaturated fat, prolonged sedentary periods or limited physical activity have major metabolic implications. In aggregate these physiological dysregulations constitute the main risk factors for the metabolic syndrome and NAFLD. The cornerstone of the treatment of NAFLD, is lifestyle changes, including modifications to diet and physical activity, to reduce body weight and liver fat, however adherence is notoriously poor and the epidemic of NAFLD continues to grow unimpeded. In the face of this unmet clinical need, the pharmacologic therapy of NAFLD has been expanding as the varied mechanistic pathways of NAFLD are elucidated. Beyond these approaches to treating NAFLD, the prevention of other liver diseases is additionally important. Chief among these is alcoholic liver disease, and heavy use is detrimental irrespective of underlying NAFLD. However, the impact of mild to moderate alcohol use in patients with mild or nonadvanced forms NAFLD is undefined. This article summarizes the results of the International Liver Transplantation Society consensus meeting on NAFLD in liver transplantation. It describes the available evidence and provides consensus guidance on the lifestyle and pharmacologic therapies of NAFLD, and the consensus position on alcohol use in patients with NAFLD.",
author = "Vlad Ratziu and Marwan Ghabril and Manuel Romero-Gomez and Gianluca Svegliati-Baroni",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/TP.0000000000002483",
language = "English (US)",
volume = "103",
pages = "28--38",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis

AU - Ratziu, Vlad

AU - Ghabril, Marwan

AU - Romero-Gomez, Manuel

AU - Svegliati-Baroni, Gianluca

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The prevalence of nonalcoholic liver disease (NAFLD) is increasing worldwide in conjunction with the epidemic increase in obesity and metabolic risk factors. Consequently, NAFLD has become a leading indication for liver transplantation. Although genetic factors play an important role in the pathogenesis of NAFLD, detrimental lifestyle trends favoring a calorically unrestricted diet rich in carbohydrates and unsaturated fat, prolonged sedentary periods or limited physical activity have major metabolic implications. In aggregate these physiological dysregulations constitute the main risk factors for the metabolic syndrome and NAFLD. The cornerstone of the treatment of NAFLD, is lifestyle changes, including modifications to diet and physical activity, to reduce body weight and liver fat, however adherence is notoriously poor and the epidemic of NAFLD continues to grow unimpeded. In the face of this unmet clinical need, the pharmacologic therapy of NAFLD has been expanding as the varied mechanistic pathways of NAFLD are elucidated. Beyond these approaches to treating NAFLD, the prevention of other liver diseases is additionally important. Chief among these is alcoholic liver disease, and heavy use is detrimental irrespective of underlying NAFLD. However, the impact of mild to moderate alcohol use in patients with mild or nonadvanced forms NAFLD is undefined. This article summarizes the results of the International Liver Transplantation Society consensus meeting on NAFLD in liver transplantation. It describes the available evidence and provides consensus guidance on the lifestyle and pharmacologic therapies of NAFLD, and the consensus position on alcohol use in patients with NAFLD.

AB - The prevalence of nonalcoholic liver disease (NAFLD) is increasing worldwide in conjunction with the epidemic increase in obesity and metabolic risk factors. Consequently, NAFLD has become a leading indication for liver transplantation. Although genetic factors play an important role in the pathogenesis of NAFLD, detrimental lifestyle trends favoring a calorically unrestricted diet rich in carbohydrates and unsaturated fat, prolonged sedentary periods or limited physical activity have major metabolic implications. In aggregate these physiological dysregulations constitute the main risk factors for the metabolic syndrome and NAFLD. The cornerstone of the treatment of NAFLD, is lifestyle changes, including modifications to diet and physical activity, to reduce body weight and liver fat, however adherence is notoriously poor and the epidemic of NAFLD continues to grow unimpeded. In the face of this unmet clinical need, the pharmacologic therapy of NAFLD has been expanding as the varied mechanistic pathways of NAFLD are elucidated. Beyond these approaches to treating NAFLD, the prevention of other liver diseases is additionally important. Chief among these is alcoholic liver disease, and heavy use is detrimental irrespective of underlying NAFLD. However, the impact of mild to moderate alcohol use in patients with mild or nonadvanced forms NAFLD is undefined. This article summarizes the results of the International Liver Transplantation Society consensus meeting on NAFLD in liver transplantation. It describes the available evidence and provides consensus guidance on the lifestyle and pharmacologic therapies of NAFLD, and the consensus position on alcohol use in patients with NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=85059176270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059176270&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002483

DO - 10.1097/TP.0000000000002483

M3 - Article

C2 - 30300289

AN - SCOPUS:85059176270

VL - 103

SP - 28

EP - 38

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -